Research summary, original research, 2017

Evaluation of radiological risk during coronary angioplasty procedures: comparison of transradial and transfemoral approaches

Iwachow P, Miechowicz I, Kałmucki P, Dziki B, Szyszka A, Baszko A, et al.. The international journal of cardiovascular imaging. 2017

Read the original paper

In plain language

In 1,500 coronary interventions, radial and femoral access had similar fluoroscopy time and patient X-ray dose, with slightly shorter procedures for radial. Staff dose was not measured, so effects on the fluoroscopy team's exposure are not known.

At a glance

Type of study
Original research, Retrospective cohort study
Who was studied
Patients
Size
n = 1,500 procedures
Summary based on
the abstract

What it found

  • Fluoroscopy time did not differ significantly between radial and femoral percutaneous coronary intervention (PCI).

    Key figures: 12.6 ± 13.5 vs. 11.7 ± 9.5 min

  • X-ray dose generated during PCI was similar for radial and femoral access.

    Key figures: 805.9 ± 615.9 vs. 792.2 ± 633.9 mGy

  • Total procedural time was shorter with radial access.

    Key figures: 43.7 ± 24.5 min vs. 47.2 ± 30.13 min, p < 0.02

  • In the radial group, older patient age correlated with longer fluoroscopy and procedural times, which was not seen with femoral access.

    Key figures: r = 0.14, p < 0.05 (FT); r = 0.07, p < 0.05 (PT)

  • PCIs in male patients used more contrast and higher X-ray dose than in female patients.

    Key figures: 887.0 ± 660.4 vs. 657.8 ± 515.2 mGy; p < 0.001

Limits to keep in mind

Single retrospective analysis reporting only patient-side dose metrics and fluoroscopy time; no operator or staff dosimetry was measured, and the country and centre are not stated in the abstract.

How this summary was made

ORSIF prepared this summary with AI assistance from the abstract of the paper. A program then checked that the passage supporting each finding appears word for word in that source. A person has not yet reviewed each summary, so read the original before relying on a number. ORSIF summarizes research and does not endorse any product or company. Report a problem with this summary.

Prepared November 3, 2026.